Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.
Industry, Sector and Symbol:
- Market Cap: £192.13 million
- Outstanding Shares: 593,443,000
- 50 Day Moving Avg: GBX 29.75
- 200 Day Moving Avg: GBX 27.73
- 52 Week Range: GBX 17.25 - GBX 33
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 54.310
- Annual Revenue: £59.98 million
- Price / Sales: 3.20
- Book Value: GBX 0.07 per share
- Price / Book: 4.98
- EBIDTA: ($4,440,000.00)
- Net Margins: 16.92%
- Return on Equity: 39.67%
- Return on Assets: 22.45%
- Average Volume: 143,377 shs.
Frequently Asked Questions for Allergy Therapeutics plc (LON:AGY)
What is Allergy Therapeutics plc's stock symbol?
Allergy Therapeutics plc trades on the London Stock Exchange (LON) under the ticker symbol "AGY."
When will Allergy Therapeutics plc make its next earnings announcement?
Where is Allergy Therapeutics plc's stock going? Where will Allergy Therapeutics plc's stock price be in 2017?
4 brokerages have issued twelve-month price objectives for Allergy Therapeutics plc's shares. Their forecasts range from GBX 45 to GBX 60. On average, they expect Allergy Therapeutics plc's stock price to reach GBX 51 in the next year. View Analyst Ratings for Allergy Therapeutics plc.
Who are some of Allergy Therapeutics plc's key competitors?
Some companies that are related to Allergy Therapeutics plc include Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH), Corium International (CORI), Aceto Corporation (ACET), Collegium Pharmaceutical (COLL), Aquinox Pharmaceuticals (AQXP), Neos Therapeutics (NEOS), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Marinus Pharmaceuticals (MRNS), Aralez Pharmaceuticals (ARLZ), Female Health Company (The) (VERU), Diurnal Group PLC (DNL), Concordia International Corp. (CXRX), BioLife Solutions (BLFS), Amryt Pharma PLC (AMYT), SCYNEXIS (SCYX) and Evoke Pharma (EVOK).
Who are Allergy Therapeutics plc's key executives?
Allergy Therapeutics plc's management team includes the folowing people:
- Manuel Llobet, Chief Executive Officer, Executive Director
- Nicolas Alexander Ulrich Wykeman, Finance Director
- Peter Sinclair Jensen, Non-Executive Chairman of the Board
- Jeff Barton, Non-Executive Director
- Tunde Otulana, Non-Executive Director
- Stephen Rushworth Smith, Senior Non-Executive Independent Director
How do I buy Allergy Therapeutics plc stock?
Shares of Allergy Therapeutics plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Allergy Therapeutics plc's stock price today?
MarketBeat Community Rating for Allergy Therapeutics plc (LON AGY)MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Allergy Therapeutics plc stock can currently be purchased for approximately GBX 32.38.
Earnings History for Allergy Therapeutics plc (LON:AGY)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Allergy Therapeutics plc (LON:AGY)
Current Year EPS Consensus Estimate: $-0.580 EPS
Dividend History for Allergy Therapeutics plc (LON:AGY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Allergy Therapeutics plc (LON:AGY)Insider Trades by Quarter for Allergy Therapeutics plc (LON:AGY)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/29/2016||Peter Jensen||Insider||Buy||30,000||GBX 19||£5,700|
|9/27/2016||Nicolas Wykeman||Insider||Buy||150,000||GBX 18||£27,000|
|7/27/2015||Llobet ,Manuel||Insider||Buy||50,000||GBX 24||£12,000|
Headline Trends for Allergy Therapeutics plc (LON:AGY)
Latest Headlines for Allergy Therapeutics plc (LON:AGY)
Allergy Therapeutics plc (AGY) Chart for Tuesday, September, 19, 2017